Myopia control efforts using NVK002 0.01% atropine exceeds the performance of a placebo, according to research presented at ...

A poster presentation explored the potential of VRDN-001 for reducing proptosis in patients with thyroid eye disease.

Complications, including pseudoexfoliation (ARR 5.7), zonular dialysis (ARR 3.3), posterior capsule rupture (PCR) (ARR 16.4), ...

Researchers evaluated the predictive effect of baseline 24-hour blood pressure on visual field loss in patients with glaucoma ...

NT-501 implantation in patients with macular telangiectasia type 2 (MacTel2) is well-tolerated and correlates with a lower ...

Patients undergoing hormone replacement therapy and long-term estrogen treatments appear to have a lower risk of glaucoma ...

A real-world faricimab study shows that, for some with nAMD, 3 loading doses, rather than 4, can be sufficient.

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib ...

Diabetic retinopathy lesions type and severity can provide prognostic details about a patients’ risk of progression.

Lithium aspartate is not effective for neurologic post-COVID-19 condition (PCC) symptoms of fatigue and cognitive dysfunction ...

A dry AMD treatment that uses a low-level light therapy device is safe, well-tolerated, and may offer functional and anatomical improvements.

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.